Table 1.
Primary diseases leading to anti-TNFα treatment implementation; number (%) of patients in all cases
| Primary disease | Patients (n = 221) | Treatments (n = 261) |
|---|---|---|
| Juvenile idiopathic arthritis | 163 (73.6) | 195 (74.7) |
| Polyarticular JIA, positive RF | 6 (2.7) | 7 (3.8) |
| Polyarticular JIA, negative RF | 40 (18.1) | 48 (18.4) |
| Oligoarticular JIA | 70 (31.7) | 88 (33.7) |
| Enthesitis-related arthritis | 24 (10.9) | 24 (9.2) |
| Psoriasic arthritis | 11 (5.0) | 13 (5.0) |
| Undifferentiated disease | 12 (5.4) | 15 (5.7) |
| Blau syndrome | 1 (0.5) | 2 (0.8) |
| Tumor necrosis factor associated periodic syndrome | 1 (0.5) | 1 (0.4) |
| PAPA syndrome | 1 (0.5) | 1 (0.4) |
| Chronic plantar fascitis | 1 (0.5) | 1 (0.4) |
| Inflammatory bowel disease | ||
| Crohn’s disease | 36 (16.3) | 39 (14.9) |
| Ulcerative colitis | 10 (4.5) | 11 (4.2) |
| Inflammatory diseases of the eye | ||
| Uveitis | 7 (3.2) | 10 (3.8) |
| Pars planitis | 1 (0.5) | 1 (0.4) |
JIA juvenile idiopathic arthritis, PAPA pyogenic arthritis, pyoderma gangrenosum and acne, RF rheumatoid factor